TY - JOUR
T1 - SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy
AU - Busca, Alessandro
AU - Lessi, Federica
AU - Verga, Luisa
AU - Candoni, Anna
AU - Cattaneo, Chiara
AU - Cesaro, Simone
AU - Dragonetti, Giulia
AU - Delia, Mario
AU - De Luca, Alessio
AU - Guglielmi, Gaspare
AU - Tumbarello, Mario
AU - Martino, Giordana
AU - Nadali, Gianpaolo
AU - Fanci, Rosa
AU - Picardi, Marco
AU - Potenza, Leonardo
AU - Nosari, Annamaria
AU - Aversa, Franco
AU - Pagano, Livio
PY - 2017
Y1 - 2017
N2 - Posaconazole demonstrated clinical superiority over fluconazole and itraconazole for prophylaxis of mold infections, although concerns exist regarding the high acquisition cost for posaconazole. In this respect, we sought to analyze the costs of antifungal prophylaxis in patients with acute myeloid leukemia (AML) who received prophylactic posaconazole (nâ=â510, 58%), itraconazole (nâ=â120, 14%) or fluconazole (nâ=â175, 20%) during induction chemotherapy. The estimated cost of antifungal prophylaxis as well as the costs of subsequent systemic antifungal therapy for treatening an invasive fungal infections (IFI) was higher in the posaconazole group compared to itraconazole and fluconazole groups. Based on the Monte Carlo simulations, the itraconazole group had the highest cost, followed by the posaconazole and fluconazole group, although the overall survival was higher in the posaconazole group as compared to the other groups. In conclusion, the cost of prophylaxis with posaconazole in AML patients compares favorably with conventional antifungal agents.
AB - Posaconazole demonstrated clinical superiority over fluconazole and itraconazole for prophylaxis of mold infections, although concerns exist regarding the high acquisition cost for posaconazole. In this respect, we sought to analyze the costs of antifungal prophylaxis in patients with acute myeloid leukemia (AML) who received prophylactic posaconazole (nâ=â510, 58%), itraconazole (nâ=â120, 14%) or fluconazole (nâ=â175, 20%) during induction chemotherapy. The estimated cost of antifungal prophylaxis as well as the costs of subsequent systemic antifungal therapy for treatening an invasive fungal infections (IFI) was higher in the posaconazole group compared to itraconazole and fluconazole groups. Based on the Monte Carlo simulations, the itraconazole group had the highest cost, followed by the posaconazole and fluconazole group, although the overall survival was higher in the posaconazole group as compared to the other groups. In conclusion, the cost of prophylaxis with posaconazole in AML patients compares favorably with conventional antifungal agents.
KW - Antifungal prophylaxis
KW - Cancer Research
KW - Hematology
KW - Oncology
KW - acute myeloid leukemia
KW - antifungal treatment
KW - cost
KW - Antifungal prophylaxis
KW - Cancer Research
KW - Hematology
KW - Oncology
KW - acute myeloid leukemia
KW - antifungal treatment
KW - cost
UR - https://publicatt.unicatt.it/handle/10807/104320
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85019226472&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019226472&origin=inward
U2 - 10.1080/10428194.2017.1318438
DO - 10.1080/10428194.2017.1318438
M3 - Article
SN - 1042-8194
VL - 58
SP - 2859
EP - 2864
JO - LEUKEMIA & LYMPHOMA
JF - LEUKEMIA & LYMPHOMA
IS - 12
ER -
